A novel variant in the COL4A3 gene: etiology of Alport syndrome type 2 in a 38-year-old male with suspected hereditary kidney disease
Author:
Sienes Bailo Paula1, Bancalero Flores José Luis1, Lahoz Alonso Raquel1, Santamaría González María1, Gutiérrez Dalmau Alex2, Álvarez de Andrés Sara3, Izquierdo Álvarez Silvia1
Affiliation:
1. Department of Clinical Biochemistry , Hospital Universitario Miguel Servet , Zaragoza , Spain 2. Department of Nephrology , Miguel Servet University Hospital , Zaragoza , Spain 3. NIMGenetics , Madrid , Spain
Abstract
Abstract
Objectives
Patients with Alport syndrome develop progressive kidney function deterioration, sensorineural hearing loss, and ocular abnormalities. This condition is caused by mutations in COL4A5 (X-linked inheritance), COL4A3 and COL4A4 (autosomal dominant or recessive inheritance), and encoding type IV collagen α3, α4, and α5, respectively. If left untreated, clinical symptoms progress from microscopic hematuria to proteinuria, progressive kidney failure, and end-stage kidney disease. At present, kidney transplantation is the only effective approach. Next-generation sequencing is the method of choice for the diagnosis of this condition.
Case presentation
We report the case of a young man with chronic kidney disease who eventually underwent transplantation. Molecular testing made it possible to determine the etiology of his clinical symptoms and autosomal recessive Alport syndrome type 2. The patient was found to be a compound heterozygote for two missense variants (trans configuration) in the COL4A3 gene: A likely pathogenic variant c.4981C>T (p.Arg1661Cys) in exon 52 inherited from the mother (described elsewhere), and another variant of uncertain significance, c.943G>A (p.Gly315Ser), in exon 17 inherited from the father that has not been previously reported in the literature or found in relevant databases.
Conclusions
Following genetic confirmation, genetic counseling was provided to the patient and his direct relatives.
Publisher
Walter de Gruyter GmbH
Reference15 articles.
1. Warady, BA, Agarwal, R, Bangalore, S, Chapman, A, Levin, A, Peter, S, et al.. Alport syndrome classification and management. Kidney Med 2020;2:639–49. https://doi.org/10.1016/j.xkme.2020.05.014. 2. Kashtan, CE. Alport syndrome. In: Adam, MP, Ardinger, HH, Pagon, RA, et al.., editors. GeneReviews®. Seattle (WA): University of Washington; 2019. 3. Nozu, K, Nakanishi, K, Abe, Y, Udagawa, T, Okada, S, Okamoto, T, et al.. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol 2019;23:158–68. https://doi.org/10.1007/s10157-018-1629-4. 4. Watson, S, Padala, SA, Bush, JS. Alport syndrome. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2021. 5. Kashtan, CE, Ding, J, Guido, G, Heidet, L, Massella, L, Nakanishi, K, et al.. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 2018;93:1045–51. https://doi.org/10.1016/j.kint.2017.12.018.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|